Peg-Intron (peginterferon alfa-2b) Powder for Injection has been approved by the FDA as a once-weekly monotherapy for the treatment of chronic hepatitis C. It is indicated for patients with compensated liver disease who were not previously treated with alpha interferon. Peg-Intron is the first pegylated interferon to be approved in the United States, and therefore offers a new treatment option for hepatitis patients.
Pegintron (peginterferon alfa-2b)
